Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.

By M. Brausi, L. Collette, K. Kurth, A. van der Meijden, W. Oosterlinck, J. Witjes, D. Newling, C. Bouffioux, R. Sylvester. European Urology, 2002

675 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. (2013, background): “The significant risk of residual tumour after initial TUR of Ta, T1 lesions has been demonstrated [36,51] (LE: 2a).”
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, methodology): “The significant risk of a residual tumour after initial TURB of TaT1 lesions has been demonstrated [37] (LE: 1b).”
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. (2009, background): “Despite complete removal of all lesions detected in white light cystoscopy (WLC), resections do not seem to be sufficiently radical in a significant fraction of cases, as residual tumour is found in up to 30–50% of cases [29,30].”
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (2017, background): “The significant risk of residual tumour after initial TURB of TaT1 lesions was demonstrated [31] (LE: 2a).”